-
Mashup Score: 0Meta-Analysis Assesses Impact of PSMA PET Imaging on Treatment Outcomes for Prostate Cancer Recurrence - 1 year(s) ago
In an interview at the recent Radiological Society of North America (RSNA) conference, Alex Pozdnyakov, M.D. discussed findings from a new meta-analysis, which revealed that prostate-specific membrane antigen/positron emission tomography (PSMA PET) imaging in patients with prostate cancer recurrence led to treatment changes that resulted in a pooled 60.2 percent rate of prostate cancer-free…
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet
-
Mashup Score: 3Meta-Analysis Assesses Impact of PSMA PET Imaging on Treatment Outcomes for Prostate Cancer Recurrence - 1 year(s) ago
In an interview at the recent Radiological Society of North America (RSNA) conference, Alex Pozdnyakov, M.D. discussed findings from a new meta-analysis, which revealed that prostate-specific membrane antigen/positron emission tomography (PSMA PET) imaging in patients with prostate cancer recurrence led to treatment changes that resulted in a pooled 60.2 percent rate of prostate cancer-free…
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
Meta-Analysis Assesses Impact of PSMA #PET Imaging on Treatment Outcomes for #ProstateCancer Recurrence https://t.co/vU5UBLSXgO @ACRRFS @ACRYPS @RadiologyACR @RSNA @SocietyAbdRad @MacRadiology @Dr_Pozdnyakov @RadiologyUcla @RadiologyUSC @UTSW_Radiology #RSNA22 #radiology https://t.co/CrvPs55kuD
-
-
Mashup Score: 0
Expert panel raised concerns and offered recommendations
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
One potential pitfall you discuss is false positives or negatives with #PSMA-#PET. What is known about this? #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/DNvw0PpKBk https://t.co/5edj3EpRXa
-
-
Mashup Score: 0
In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [177Lu]Lu-PSMA-617 than cabazitaxel, which provides guidance for optimal [177Lu]Lu-PSMA-617 use. High FDG-PET MTV was associated with lower responses regardless of randomly assigned treatment, warranting further research for treatment intensification. A…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Presented at #EANM22, now in the Nov issue: #PSMA and FDG-#PET as #predictive and #prognostic #biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant #prostatecancer https://t.co/DC2GpyVt6t
-
-
Mashup Score: 0Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer? - 2 year(s) ago
In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
Video: Could an Emerging PSMA/#PET Agent Improve Detection of Recurrent #ProstateCancer? https://t.co/31E4XNyacM @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad @SAR_AARC @PennRadiology @EmoryUniversity @DukeRadiology @BraccoDiag @BlueEarthDx #radiology #RadRes https://t.co/fqTyvpOfrK
-
-
Mashup Score: 0Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer? - 2 year(s) ago
In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
Video: Could an Emerging PSMA/#PET Agent Improve the Detection of Recurrent #ProstateCancer? https://t.co/yseuWukLp9 @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @PennRadiology @StanfordRad @UTSW_Radiology @EmoryRadiology @UNCRadiology @DukeRadiology #radiology #ASTRO22 https://t.co/h9ocsWkR1J
-
-
Mashup Score: 5Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma - Journal of Neuro-Oncology - 2 year(s) ago
Purpose In-field high-grade glioma (HGG) recurrence is a common challenge with limited treatment options, including re-irradiation. The radiotracer 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-DOPA) crosses the blood brain barrier and demonstrates high uptake in tumor, but low uptake in normal tissue. This study investigated whether 18F-DOPA positron emission tomography (PET) and MRI guided…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
18F-DOPA #PET-guided re-irradiation for progressive high-grade #glioma appears safe and promising for further investigation @wgbreen @n_laack @DavidRoutmanMD @MRuff100 @AnitaMahajanMD @ASTRO_org @MayoCancerCare @MayoRadOnc #radonc https://t.co/Bks0E9a4ej https://t.co/8yU1Pw1mcT
-
-
Mashup Score: 0Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer? - 2 year(s) ago
In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
Video: Could an Emerging PSMA/#PET Agent Improve Detection of Recurrent #ProstateCancer?https://t.co/YffgtrB5AO @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad @ASTRO_org @PennRadiology @EmoryRadiology @DukeRadiology @BlueEarthDx @BraccoDiag #radiology #ASTRO22 https://t.co/8maZwZDMyW
-
-
Mashup Score: 1
Purpose : Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) are common. This study aims to define variables that predict whether such lesions are likely malignant or benign using features on PSMA PET/CT. Methods : 18F-DCFPyL PET/CT imaging was performed in 243 consecutive patients with high-risk primary or…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Predicting Outcomes of Indeterminate Bone Lesions on 18F #DCFPyL #PSMA #PET/CT Scans in the Setting of High-Risk Primary or Recurrent #ProstateCancer @radiolobt @PChoyke @NCICCR_MIP @theNCI @DrSHarmon @gulleyj1 @billdahutmd https://t.co/p4fiUVBgZC
-
-
Mashup Score: 0
One prospective multicenter study found the radiohybrid prostate-specific membrane antigen (PSMA) agent 18F-rhPSMA-7.3 had an 83 percent detection rate in nearly 400 men with suspected prostate cancer.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA to Review Emerging #PSMA/#PET Agent for #ProstateCancer https://t.co/WoKByhoo9O @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SAR_AARC @SocietyAbdRad @BlueEarthDx @BraccoDiag @RadiologyUcla @StanfordRad @UTSW_Radiology @OHSURadiology @RadiologyUSC #radiology #RadRes https://t.co/1Lhxjsz2Bk
-
What a New Meta-Analysis Reveals About PSMA #PET Imaging and Treatment Outcomes for #ProstateCancer Recurrence https://t.co/qJ5q4Eut5A @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad @PennRadiology @MacRadiology @UABRadiology @YaleRadiology #RSNA22 #radiology https://t.co/2072F9pLLj